Empagliflozin 10 mg

Empagliflozin 25 mg

Empaxa contains the active substance empagliflozin which is a high selective inhibitor of sodium-glucose co-transporter 2 (SGLT2).

• Highly effective treatment for type T2DM at any disease stage.
• Has cardioprotective benefits and significantly reduces cardiovascular deaths and hospitalization.
• Has Renoprotective benefits and improves renal outcomes.
• Can be used as monotherapy and in combination with other anti-diabetic agents.
• Low risk of hypoglycemia.
• Exerts a favorable effect on nonglycemic outcomes, including blood pressure and body weight.
• Empagliflozin is generally well-tolerated as monotherapy or as add-on therapy.
• Offers high convivence once-daily regimen.